ST凯利(300326.SZ)拟将对动之医学持股比例提高至50.9014% 其主营再生诱导系列产品

智通财经2025-11-21

智通财经APP讯，ST凯利(300326.SZ)公告，公司拟通过受让股权并认购新增注册资本的方式对动之医学技术(上海)有限公司(简称“动之医学”)进行投资。公告显示，动之医学是一家致力于研发、生产和销售再生诱导系列产品(包括再生诱导生物补片、再生诱导活细胞补片、脐带干细胞制剂、羊膜凝胶敷料等产品)的企业，其注册资本为178.3679万元。截至目前，公司已持有动之医学37.9528%的股权(对应...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2585115235?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-11-21 17:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2585115235","market":"us","top_or_hot":-1,"title":"ST凯利(300326.SZ)拟将对动之医学持股比例提高至50.9014% 其主营再生诱导系列产品","media":"智通财经","content":"<div>\n<p>智通财经APP讯，ST凯利(300326.SZ)公告，公司拟通过受让股权并认购新增注册资本的方式对动之医学技术(上海)有限公司(简称“动之医学”)进行投资。公告显示，动之医学是一家致力于研发、生产和销售再生诱导系列产品(包括再生诱导生物补片、再生诱导活细胞补片、脐带干细胞制剂、羊膜凝胶敷料等产品)的企业，其注册资本为178.3679万元。截至目前，公司已持有动之医学37.9528%的股权(对应...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1372107.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ST凯利(300326.SZ)拟将对动之医学持股比例提高至50.9014% 其主营再生诱导系列产品</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nST凯利(300326.SZ)拟将对动之医学持股比例提高至50.9014% 其主营再生诱导系列产品\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-11-21 17:16 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1372107.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，ST凯利(300326.SZ)公告，公司拟通过受让股权并认购新增注册资本的方式对动之医学技术(上海)有限公司(简称“动之医学”)进行投资。公告显示，动之医学是一家致力于研发、生产和销售再生诱导系列产品(包括再生诱导生物补片、再生诱导活细胞补片、脐带干细胞制剂、羊膜凝胶敷料等产品)的企业，其注册资本为178.3679万元。截至目前，公司已持有动之医学37.9528%的股权(对应...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1372107.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"300326","symbol_name":"ST凯利","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1372107.html","article_id":"2585115235","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2585115235","pubTimestamp":1763716575,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，ST凯利 公告，公司拟通过受让股权并认购新增注册资本的方式对动之医学技术(上海)有限公司进行投资。公告显示，动之医学是一家致力于研发、生产和销售再生诱导系列产品的企业，其注册资本为178.3679万元。上述交易完成后，公司对动之医学的持股比例从37.9528%增加至50.9014%。据悉，动之医学的生物补片产品提高了公司在研发及生产再生诱导系列产品领域的竞争力，目前产品已经完成上市前临床试验。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"300326":"ST凯利","BK0251":"专用设备"},"translate_title":"ST Kelly (300326. SZ) plans to increase its shareholding ratio in Dongzhi Medicine to 50.9014%, its main regeneration induction series products","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"300326":1.5},"content_text":"智通财经APP讯，ST凯利(300326.SZ)公告，公司拟通过受让股权并认购新增注册资本的方式对动之医学技术(上海)有限公司(简称“动之医学”)进行投资。公告显示，动之医学是一家致力于研发、生产和销售再生诱导系列产品(包括再生诱导生物补片、再生诱导活细胞补片、脐带干细胞制剂、羊膜凝胶敷料等产品)的企业，其注册资本为178.3679万元。截至目前，公司已持有动之医学37.9528%的股权(对应注册资本67.6957万元)。股东上海立赛管理咨询合伙企业(有限合伙)(简称“立赛管理”)、袁征将退出动之医学，公司同意受让立赛管理、袁征持有的动之医学股权;同时，公司将对动之医学进行增资2000万。上述交易完成后，公司对动之医学的持股比例从37.9528%增加至50.9014%。据悉，动之医学的生物补片产品提高了公司在研发及生产再生诱导系列产品领域的竞争力，目前产品已经完成上市前临床试验。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2585115235","isCrawlerRequest":true}